Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$3.08 - $8.73 $120,120 - $340,470
39,000 New
39,000 $120,000
Q3 2020

Nov 13, 2020

BUY
$8.09 - $16.25 $2.24 Million - $4.5 Million
277,071 New
277,071 $2.46 Million

Others Institutions Holding PSTX

About Poseida Therapeutics, Inc.


  • Ticker PSTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 85,775,600
  • Market Cap $810M
  • Description
  • Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...
More about PSTX
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.